Chlorcyclizine/Pseudoephedrine

Pronunciation: klor-SYE-klih-zeen/SOO-doe-e-FED-rin
Generic Name: Chlorcyclizine/Pseudoephedrine
Brand Name: Stahist AD

Chlorcyclizine/Pseudoephedrine is used for:

Relieving symptoms of sinus congestion; pressure; runny nose; itching of the nose or throat; itchy, watery eyes; and sneezing due to colds, hay fever, or allergies. It may also be used for other conditions as determined by your doctor.

Chlorcyclizine/Pseudoephedrine is an antihistamine and decongestant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, which relieves congestion and pressure.

Do NOT use Chlorcyclizine/Pseudoephedrine if:

• you are allergic to any ingredient in Chlorcyclizine/Pseudoephedrine


• you have severe or uncontrolled high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems


• you are unable to urinate or are having an asthma attack


• you take droxidopa or sodium oxybate (GHB), or you have taken furazolidone or a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Chlorcyclizine/Pseudoephedrine:

Some medical conditions may interact with Chlorcyclizine/Pseudoephedrine. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, plan to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of adrenal gland problems (eg, adrenal gland tumor); heart problems (eg, cor pulmonale; fast, slow, or irregular heartbeat; heart disease); high blood pressure; diabetes; blood vessel problems; stroke; glaucoma or increased pressure in the eye; seizures; thyroid problems; or trouble sleeping


• if you have a history of asthma, chronic obstructive pulmonary disease (COPD), or other lung or breathing problems (eg, chronic bronchitis, emphysema); chronic cough; or sleep apnea


• if you have a blockage of your bladder, stomach, or bowels; ulcers; an enlarged prostate or other prostate problems; or trouble urinating


• if you are taking medicine for high blood pressure

Some MEDICINES MAY INTERACT with Chlorcyclizine/Pseudoephedrine. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased


• Beta-blockers (eg, propranolol), furazolidone, linezolid, MAOIs (eg, phenelzine), sodium oxybate (GHB), tricyclic antidepressants (eg, amitriptyline), or urinary alkalinizers (eg, sodium bicarbonate) because they may increase the risk of Chlorcyclizine/Pseudoephedrine's side effects


• Bromocriptine or hydantoins (eg, phenytoin) because the risk of their side effects may be increased by Chlorcyclizine/Pseudoephedrine


• Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Chlorcyclizine/Pseudoephedrine

This may not be a complete list of all interactions that may occur. Ask your health care provider if Chlorcyclizine/Pseudoephedrine may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Chlorcyclizine/Pseudoephedrine:

Use Chlorcyclizine/Pseudoephedrine as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Chlorcyclizine/Pseudoephedrine by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.


• If you miss a dose of Chlorcyclizine/Pseudoephedrine and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Chlorcyclizine/Pseudoephedrine.

Important safety information:

• Chlorcyclizine/Pseudoephedrine may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Chlorcyclizine/Pseudoephedrine with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do not drink alcohol while you are using Chlorcyclizine/Pseudoephedrine.


• Check with your doctor before you use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Chlorcyclizine/Pseudoephedrine; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Do not take diet or appetite control medicines while you are taking Chlorcyclizine/Pseudoephedrine without checking with your doctor.


• Before you start any new medicine, check the label to see if it has a decongestant or an antihistamine in it too. If it does or if you are not sure, check with your doctor or pharmacist.


• Do NOT take more than the recommended dose or take Chlorcyclizine/Pseudoephedrine for longer than prescribed without checking with your doctor.


• If your symptoms do not get better within 7 days, if they get worse, if they occur along with a fever, or if new symptoms occur, check with your doctor.


• Chlorcyclizine/Pseudoephedrine may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Chlorcyclizine/Pseudoephedrine. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.


• Chlorcyclizine/Pseudoephedrine may interfere with skin allergy tests. If you are scheduled for a skin test, talk to your doctor. You may need to stop taking Chlorcyclizine/Pseudoephedrine for a few days before the tests.


• Tell your doctor or dentist that you take Chlorcyclizine/Pseudoephedrine before you receive any medical or dental care, emergency care, or surgery.


• Use Chlorcyclizine/Pseudoephedrine with caution in the ELDERLY; they may be more sensitive to its effects, especially confusion, dizziness, drowsiness, dry mouth, excitability, low blood pressure, and trouble urinating.


• Caution is advised when using Chlorcyclizine/Pseudoephedrine in CHILDREN; they may be more sensitive to its effects, especially excitability.


• Chlorcyclizine/Pseudoephedrine should not be used in CHILDREN younger than 6 years old without first checking with the child's doctor; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Chlorcyclizine/Pseudoephedrine while you are pregnant. Chlorcyclizine/Pseudoephedrine may be found in breast milk. Do not breast-feed while taking Chlorcyclizine/Pseudoephedrine.

Possible side effects of Chlorcyclizine/Pseudoephedrine:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Anxiety; constipation; diarrhea; dizziness; drowsiness; dry mouth, nose, or throat; excitability; headache; loss of appetite; nausea; trouble sleeping; upset stomach; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching, difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; difficulty urinating or inability to urinate; fast or irregular heartbeat; fever, chills, or persistent sore throat; hallucinations; mental or mood changes (eg, nervousness); persistent trouble sleeping; restlessness; seizures; severe or persistent dizziness, drowsiness, light-headedness, or headache; tremor; vision changes (eg, blurred vision).

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Chlorcyclizine/Pseudoephedrine side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; ringing in the ears; seizures; severe dizziness, light-headedness, or headache; severe drowsiness; unusually fast, slow, or irregular breathing; unusually fast, slow, or irregular heartbeat; vomiting.

Proper storage of Chlorcyclizine/Pseudoephedrine:

Store Chlorcyclizine/Pseudoephedrine at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Chlorcyclizine/Pseudoephedrine out of the reach of children and away from pets.

General information:

• If you have any questions about Chlorcyclizine/Pseudoephedrine, please talk with your doctor, pharmacist, or other health care provider.


• Chlorcyclizine/Pseudoephedrine is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Chlorcyclizine/Pseudoephedrine. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Chlorcyclizine/Pseudoephedrine resources

• Chlorcyclizine/Pseudoephedrine Side Effects (in more detail)
• Chlorcyclizine/Pseudoephedrine Use in Pregnancy & Breastfeeding
• Chlorcyclizine/Pseudoephedrine Drug Interactions
• Chlorcyclizine/Pseudoephedrine Support Group
• 0 Reviews · Be the first to review/rate this drug

Ulipristal Acetate

Class: Contraceptives
VA Class: HS200
Chemical Name: 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11β)-
Molecular Formula: C₃₀H₃₇NO₄
CAS Number: 126784-99-4
Brands: ella

Introduction

Postcoital contraceptive; synthetic selective progesterone receptor modulator.^{1 2 3 6 13 14}

Uses for Ulipristal Acetate

Postcoital Contraception

Prevention of unintended pregnancy after unprotected intercourse or known or suspected contraceptive failure as an emergency contraceptive.^{1 2 3 6 13 14} Postcoital (emergency) contraceptive regimens are not as effective as most other methods of long-term contraception;not intended for routine use as a contraceptive.^{1 5 14}

Levonorgestrel currently is the preferred postcoital contraceptive when the drug is initiated within 72 hours of unprotected intercourse.^{5 14 15 16 17} Ulipristal is an effective alternative to levonorgestrel for postcoital contraception when used within 120 hours after unprotected intercourse.^{1 2 3}

Ulipristal Acetate Dosage and Administration

Administration

Administer orally without regard to meals.¹

Administer as soon as possible but within 120 hours following unprotected intercourse.^{1 2 3}

May be used at any time during the menstrual cycle.¹

If vomiting occurs within 3 hours after administration, consider repeating the dose.¹

Dosage

Available as ulipristal acetate; dosage expressed in terms of the salt.¹

Adults

Postcoital Contraception

Oral

Single 30-mg dose taken within 120 hours of unprotected intercourse or known or suspected contraceptive failure.^{1 2 3}

Special Populations

No special population dosage recommendations at this time.¹

Cautions for Ulipristal Acetate

Contraindications

• 
  

  Known or suspected pregnancy.¹

  
  

Warnings/Precautions

Warnings

Fetal/Neonatal Morbidity and Mortality

May cause fetal harm; exclude pregnancy before initiating treatment.¹ Embryofetal death reported in animals, but no adequate and well-controlled studies to date in pregnant women.¹ If inadvertently used during pregnancy, apprise of potential fetal hazard.¹

Existing Pregnancy

Not intended for termination of existing pregnancy; exclude possibility of pregnancy prior to administration.¹ Perform pregnancy testing if pregnancy cannot be excluded on basis of history and/or physical examination.¹

Follow-up physical and/or pelvic examination recommended if there is concern regarding general health or pregnancy status of women receiving the drug.¹

Ectopic Pregnancy

Consider possibility of ectopic pregnancy in women who become pregnant or complain of severe lower abdominal pain.¹ Manufacturer states that history of ectopic pregnancy is not considered a contraindication to use.¹

Repeated Use

Intended for occasional use as emergency contraceptive.¹ Postcoital (emergency) contraceptive regimens are not as effective as most other methods of long-term contraception; not intended for routine use as a contraceptive.^{1 5 14} Repeated use within the same menstrual cycle not recommended; safety and efficacy of such repeated use not evaluated.¹

Fertility Following Use

Rapid return of fertility likely following treatment for emergency contraception; continue or initiate routine methods of contraception as soon as possible to prevent pregnancy.^{1 4}

Ulipristal may reduce the efficacy of other hormonal contraceptives.¹ (See Drug Interactions.) Reliable barrier contraceptives (e.g., condom with spermicide) recommended in women for subsequent acts of intercourse within the same menstrual cycle after receiving ulipristal.¹

Effect on Menstrual Cycle

Onset of menstruation may occur a few days earlier or later than expected.^{1 2 3 8} If menstruation delayed by >1 week, rule out pregnancy.¹ Intermenstrual bleeding also reported.¹

HIV and STDs

Does not protect against HIV infection or other sexually transmitted diseases (STDs).¹

Specific Populations

Pregnancy

Category X.¹ (See Fetal/Neonatal Morbidity and Mortality and also see Contraindications under Cautions.)

Lactation

Distributed into milk in rats; not known whether distributed into human milk.¹ Use not recommended.¹

Pediatric Use

Safety and efficacy established in women of reproductive age.¹ Safety and efficacy expected to be identical for postpubertal adolescents <18 years of age and women ≥18 years of age.¹ Not intended for use before menarche.¹

Geriatric Use

Not evaluated in women ≥65 years of age and not intended for use in postmenopausal women.¹

Hepatic Impairment

Not studied in patients with hepatic impairment.¹

Renal Impairment

Not studied in patients with renal impairment.¹

Common Adverse Effects

Headache,^{1 2 3 6} abdominal pain,^{1 2 3 6} nausea,^{1 2 3 6} dysmenorrhea,^{1 2 3} fatigue,^{1 2 3 6} dizziness.^{1 2 3 6}

Interactions for Ulipristal Acetate

Appears to be principally metabolized by CYP3A4.^{1 10} No evidence of induction or inhibition of CYP isoenzymes from in vitro studies.¹

Specific Drugs

Drug	Interaction	Comments
Anticonvulsants (carbamazepine, felbamate, oxcarbazepine, phenytoin, topiramate)	Possible decrease in plasma concentrations and efficacy of ulipristal1
Antifungal agents, azole (itraconazole, ketoconazole)	Possible increase in plasma concentrations of ulipristal1
Barbiturates (e.g., phenobarbital)	Possible decrease in plasma concentrations and efficacy of ulipristal1
Bosentan	Possible decrease in plasma concentrations and efficacy of ulipristal1
Griseofulvin	Possible decrease in plasma concentrations and efficacy of ulipristal1
Hormonal contraceptives	May reduce efficacy of other hormonal contraceptives as a result of high-affinity binding to progesterone receptors1	Recommend reliable barrier contraceptives (e.g., condom with spermicide) for subsequent acts of intercourse within the same menstrual cycle1
Rifampin	Possible decrease in plasma concentrations and efficacy of ulipristal1
St. John's wort (Hypericum perforatum)	Possible decrease in plasma concentrations and efficacy of ulipristal1

Ulipristal Acetate Pharmacokinetics

Absorption

Bioavailability

Rapidly absorbed following oral administration with peak plasma concentrations attained within 60–90 minutes.^{1 8}

Food

High-fat meal reduces peak plasma concentrations by 40–45% and delays time to peak plasma concentrations from median of 0.75 to 3 hours.¹ However, food not expected to result in clinically important effects on efficacy or safety.¹

Distribution

Plasma Protein Binding

>94% (mainly HDL-cholesterol, alpha-1-acid glycoprotein, albumin).^{1 10}

Elimination

Metabolism

In vitro data indicate metabolism is predominantly mediated by CYP3A4 in the liver to mono-demethylated (active) and di-demethylated (inactive) metabolites.^{1 8}

Half-life

About 32 hours.^{1 14}

Stability

Storage

Oral

Tablets

20–25°C.¹ Protect from light.¹

Actions

• 
  

  Exhibits antagonist activity at progesterone receptors and inhibits progesterone from binding to its receptors; also possesses partial agonist activity at progesterone receptors.^{1 7 9 11 14}

  
  


• 
  

  Contraceptive effects may involve inhibition or delay of ovulation, inhibition of follicular growth or rupture, and/or alteration of the endometrium possibly affecting implantation.^{1 4 10 11 12 13} At recommended doses for postcoital contraception, no clinically important effects on the endometrium.^{2 14}

  
  

Advice to Patients

• 
  

  Importance of reading the patient information (medication guide) provided by the manufacturer before initiating therapy.¹

  
  


• 
  

  Importance of administering as soon as possible and not >120 hours after unprotected intercourse or known or suspected contraceptive failure.¹

  
  


• 
  

  Importance of women informing a clinician if pregnancy is known or suspected.¹ Do not use for termination of existing pregnancy.¹

  
  


• 
  

  Importance of women informing a clinician if vomiting occurs within 3 hours of administration and to discuss the need for a repeat dose.¹

  
  


• 
  

  Importance of advising women to seek medical attention if severe lower abdominal pain occurs 3–5 weeks after administration to rule out possibility of ectopic pregnancy.¹

  
  


• 
  

  Importance of women contacting a clinician if menstruation delayed >1 week beyond the expected date to rule out possibility of pregnancy.¹

  
  


• 
  

  Importance of advising women not to use the drug routinely for contraception and not to repeat use within the same menstrual cycle.¹

  
  


• 
  

  Importance of informing women that ulipristal may reduce the efficacy of other hormonal contraceptives and to use reliable barrier contraceptives (e.g., condom with spermicide) for subsequent acts of intercourse within the same menstrual cycle.^{1 5}

  
  


• 
  

  Importance of advising women not to use the drug while breast-feeding.¹

  
  


• 
  

  Importance of advising women that ulipristal is not effective in all cases; drug may be less effective in women with body mass index >30 kg/m².¹

  
  


• 
  

  Importance of informing women that ulipristal does not protect against HIV-infection (AIDS) or other STDs.¹

  
  


• 
  

  Importance of women informing a clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal supplements, as well as any concomitant illnesses.¹

  
  


• 
  

  Importance of informing patients of other important precautionary information.¹ (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Ulipristal Acetate

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Tablets	30 mg	ella	Watson

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions June 21, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

1. Watson Pharma. ella (ulipristal acetate) tablets prescribing information. Morristown, NJ; 2010 Aug.

2. Glasier AF, Cameron ST, Fine PM et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010; 375:555-62. [PubMed 20116841]

3. Fine P, Mathé H, Ginde S et al. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol. 2010; 115:257-63. [PubMed 20093897]

4. Brache V, Cochon L, Jesam C et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod. 2010; 25:2256-63. [PubMed 20634186]

5. American Academy of Pediatrics Committee on Adolescence. Emergency contraception. Pediatrics. 2005; 116:1026-35. [PubMed 16147972]

6. Creinin MD, Schlaff W, Archer DF et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol. 2006; 108:1089-97. [PubMed 17077229]

7. Attardi BJ, Burgenson J, Hild SA et al. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004; 88:277-88. [PubMed 15120421]

8. Blithe DL, Nieman LK, Blye RP et al. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003; 68:1013-7. [PubMed 14667994]

9. Chabbert-Buffet N, Meduri G, Bouchard P et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005 May-Jun; 11:293-307. [PubMed 15790602]

10. Gainer EE, Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids. 2003; 68:1005-11. [PubMed 14667993]

11. Passaro MD, Piquion J, Mullen N et al. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Hum Reprod. 2003; 18:1820-7. [PubMed 12923133]

12. Stratton P, Hartog B, Hajizadeh N et al. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod. 2000; 15:1092-9. [PubMed 10783359]

13. Stratton P, Levens ED, Hartog B et al. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril. 2010; 93:2035-41. [PubMed 19200989]

14. Gemzell-Danielsson K, Rabe T. Emergency contraception. J Reproduktionsmed Endokrinol. 2010; 7 (Sonderheft 1): 73-77.

15. Glasier A. Emergency postcoital contraception. N Engl J Med. 1997; 337:1058-64. [PubMed 9321535]

16. . Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet. 1998; 352:428-33. [PubMed 9708750]

17. von Hertzen H, Piaggio G, Ding J et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet. 2002; 360:1803-10. [PubMed 12480356]

18. Hild SA, Reel JR, Hoffman LH et al. CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod. 2000; 15:822-9. [PubMed 10739827]

More Ulipristal Acetate resources

• Ulipristal Acetate Side Effects (in more detail)
• Ulipristal Acetate Dosage
• Ulipristal Acetate Use in Pregnancy & Breastfeeding
• Ulipristal Acetate Drug Interactions
• Ulipristal Acetate Support Group
• 1 Review for Ulipristal Acetate - Add your own review/rating

Compare Ulipristal Acetate with other medications

• Birth Control
• Emergency Contraception
• Uterine Fibroids

ClindaReach Pledget

Generic Name: clindamycin topical (klin da MYE sin)

Brand Names: Cleocin T, Clindagel, ClindaMax, ClindaReach Pledget, Evoclin

What is ClindaReach Pledget (clindamycin topical)?

Clindamycin is an antibiotic. Clindamycin topical prevents bacteria from growing on the skin.

Clindamycin topical (for the skin) is used to treat severe acne.

Clindamycin topical may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about ClindaReach Pledget (clindamycin topical)?

Use clindamycin topical exactly as your doctor has prescribed it for you. Using more medicine or applying it more often than prescribed will not make it work any faster, and may increase side effects. Do not use this medication for longer than your doctor has prescribed.

Avoid getting this medication in your eyes. If it does get into your eyes, rinse thoroughly with water.

It may take several weeks of using this medicine before your symptoms improve. For best results, keep using the medication as directed. Talk with your doctor if your symptoms do not improve.

Although this medicine is applied to the skin, your body may absorb enough clindamycin to cause serious side effects. You may not be able to use this medication if you have inflammation of your intestines (also called enteritis), ulcerative colitis, or if you have ever had severe diarrhea caused by antibiotic medicine.

What should I discuss with my healthcare provider before using ClindaReach Pledget (clindamycin topical)?

You should not use this medication if you are allergic to clindamycin or if you have:

• 
  

  inflammation of your intestines (also called enteritis);

  
  


• 
  

  ulcerative colitis; or

  
  


• 
  

  if you have ever had severe diarrhea caused by antibiotic medicine.

  
  

FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether clindamycin topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not use this medication on a child younger than 12 years old without the advice of a doctor.

How should I use ClindaReach Pledget (clindamycin topical)?

Use clindamycin topical exactly as your doctor has prescribed it for you. Using more medicine or applying it more often than prescribed will not make it work any faster, and may increase side effects. Do not use this medication for longer than your doctor has prescribed.

This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.

Wash your hands before and after applying this medication.

Wash your face with a mild soap or cleanser and pat the skin dry with a clean towel.

Avoid getting this medication in your eyes. If it does get into your eyes, rinse thoroughly with water.

It may take several weeks of using this medicine before your symptoms improve. For best results, keep using the medication as directed. Talk with your doctor if your symptoms do not improve.

Store this medication at room temperature away from moisture and heat. Keep the clindamycin topical foam canister away from an open flame or high heat. Do not puncture the canister or throw an empty canister into a fire.

What happens if I miss a dose?

Apply the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to apply the medicine and skip the missed dose. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms include bloody or watery diarrhea, which may result if you absorb this medicine through your skin by applying too much.

What should I avoid while taking ClindaReach Pledget (clindamycin topical)?

Do not smoke while using clindamycin topical foam, or immediately after applying it. The contents of the foam canister are flammable.

Avoid using skin products that can cause irritation, such as harsh soaps, shampoos, or skin cleansers, hair coloring or permanent chemicals, hair removers or waxes, or skin products with alcohol, spices, astringents, or lime. Do not use other medicated skin products unless your doctor has told you to.

Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or has blood in it, call your doctor. Do not use any medicine to stop the diarrhea unless your doctor has told you to.

ClindaReach Pledget (clindamycin topical) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medicine and call your doctor at once if you have any of these serious side effects:

• 
  

  severe redness, itching, or dryness of treat skin areas; or

  
  


• 
  

  diarrhea that is watery or bloody.

  
  

Less serious side effects may include:

• 
  

  mild burning or itching;

  
  


• 
  

  mild dryness of treated skin; or

  
  


• 
  

  redness or other irritation.

  
  

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect ClindaReach Pledget (clindamycin topical)?

Before using clindamycin topical, tell your doctor if you are using any of the following drugs:

• 
  

  erythromycin topical (Akne-Mycin, Emcin Clear, Eryderm, Erygel, Erythra-Derm, Ery-Sol, and others); or

  
  


• 
  

  erythromycin taken by mouth (E.E.S., E-Mycin, Ery-Tab, E-Mycin, Robimycin, and others).

  
  

This list is not complete and there may be other drugs that can interact with clindamycin topical. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

More ClindaReach Pledget resources

• ClindaReach Pledget Side Effects (in more detail)
• ClindaReach Pledget Use in Pregnancy & Breastfeeding
• ClindaReach Pledget Drug Interactions
• ClindaReach Pledget Support Group
• 0 Reviews for ClindaReach Pledget - Add your own review/rating

• Clindamycin Topical Prescribing Information (FDA)


• Cleocin T Gel MedFacts Consumer Leaflet (Wolters Kluwer)


• Cleocin T Topical Advanced Consumer (Micromedex) - Includes Dosage Information


• Cleocin Vaginal Advanced Consumer (Micromedex) - Includes Dosage Information


• Clinda-Derm Prescribing Information (FDA)


• ClindaMax Cream MedFacts Consumer Leaflet (Wolters Kluwer)


• Clindacin P Prescribing Information (FDA)


• Clindagel Prescribing Information (FDA)


• Clindamax Prescribing Information (FDA)


• Clindesse Cream MedFacts Consumer Leaflet (Wolters Kluwer)


• Clindesse Consumer Overview


• Clindesse Prescribing Information (FDA)


• Evoclin Prescribing Information (FDA)


• Evoclin Foam MedFacts Consumer Leaflet (Wolters Kluwer)


• Evoclin Consumer Overview

Compare ClindaReach Pledget with other medications

• Acne
• Perioral Dermatitis

Where can I get more information?

• Your pharmacist can provide more information about clindamycin topical.

See also: ClindaReach Pledget side effects (in more detail)

Vitafol One

Dosage Form: capsule, gelatin coated
Product Information.

Contraindications

Vitafol-One is contraindicated in patients with hypersensitivity to any of its components or color additives.

Folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid.

Iron Therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.), pyridoxine responsive anemia, or cirrhosis of the liver.

Cyanocobalamin is contraindicated in patients with sensitivity to cobalt or to cyanocobalamin (Vitamin B12).

Boxed Warning

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6.  Keep this product out of the reach of children.  In case of accidental overdose, call a doctor or a Poison Control Center immediately.

WARNINGS/PRECAUTIONS:

Vitafol-One should be used with caution in patients with known sensitivity or allergy to soy.


Vitamin D supplementation should be used with caution in those with hypercalcemia or conditions that may lead to hypercalcemia such as hyperparathyroidism and those who form calcium-containing kigney stones.  High doses of vitamin D can lead to elevated levels of calcium that reside in the blood and soft tissues.  Bone pain, high blood pressure, formation of kidney stones, renal failure, and increased risk of heart disease can occur.


Iodine should be used with caution in patients with an overactive thyroid.


Prolonged use of iron salts may produce iron storage disease.


Folic acid, especially in doses above 0.1 mg daily, may obscure pernicious anemia, in that hematologic remission may occur while neurological manifestations remain progressive.


The use of folic acid doses above 1 mg daily may precipitate or exacerbate the neurological damage of vitamin B12 deficiency.


Consumption of more than 3 grams of omega-3 fatty acids per day from all sources may lead to excessive bleeding.  Supplemental intake of omega-3 fatty acids such as DHA exceeding 2 grams per day is not recommended.


Avoid Overdosage.  Keep out of the reach of children.


Drug Interactions:


Medications for an overactive thyroid (anti-thyroid drugs) used in conjunction with iodine supplementation may lead to hypothyroidism.


Medications for hypertension used in conjunction with iodine supplementation may increase potassium.


High doses of folic acid may result in decreased serum levels of the anticonvulsant drugs;carbamazepine, fosphenytoin, phenytoin, phenobarbitol, valproic acid.  Folic acid may decrease a patient's response to methotrexate.


Vitamin D supplementation should not be given with large amounts of calcium in those with hypercalcemia or conditions that may lead to hypercalcemia such as hyperparathyroidism and those who form calcium-containing kidney stones.


Zinc can inhibit the absorption of certain antibiotics; taken at least 2 hours apart to minimize interactions.


Consult appropriate references for additional specific vitamin-drug interactions.


Information for Patients: Patients should be counseled to disclose all medical conditions, including use of all medications, vitamins and supplements, pregnancy, and breast-feeding.


Pediatric Use: Not for pediatric use. 

Adverse Reactions

Adverse reactions have been reported with specific vitamins and minerals, but generally at doses substantially higher than those in Vitafol-One.  However, allergic and idiosyncratic reactions are possible at any dose.  Reported adverse events include skin ailments, gastrointestinal complaints, glucose abnormalities, and visual problems.

Dosage and Administration

Before, during and after pregnancy, one softgel capsule daily, or as directed by a physician.

How Supplied

Vitafol-One is available as a dark blue, oval shaped softgel capsule imprinted "EV0070".  Avialable in Box of Unit-Dose pack of 30 (5 child resistant blister cards of 6 softgel capsules), (NDC 0642-0070-30) and as professional samples (NDC 0642-0070-01).

Store at room temperature, approximately 15-30C (59-86F), avoid excessive heat.

Rx Only

Manufactured for

EVERETT LABORATORIES, INC.

West Orange, NJ 07052

1-877-324-9349

Principal Display Panel

Principal Display Panel

VITAFOL  ONE prenatal supplement with dha  capsule, gelatin coated

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 0642-0070 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Vitamin A (Beta Carotene) Beta Carotene 1100 [iU] Ascorbic Acid (Ascorbic Acid) Ascorbic Acid 30 mg Thiamine Mononitrate (Thiamine ) Thiamine Mononitrate 1.6 mg Riboflavin (Riboflavin) Riboflavin 1.8 mg Niacin (Niacinamide) Niacinamide 15 mg Pyridoxine Hydrochloride (Pyridoxine) Pyridoxine 2.5  mg Cyanocobalamin (Cyanocobalamin) Cyanocobalamin .012 mg Folic Acid (Folic Acid) Folic Acid 1 mg Iodine (Iodine) Iodine 0.150 mg Magnesium (Magnesium Oxide) Magnesium Oxide 20 mg Zinc (Zinc Oxide) Zinc Oxide 25 mg Copper (Cupric Oxide) Cupric Oxide 2 mg Vitamin D (Cholecalciferol) Cholecalciferol 1000 [iU] Omega-3 Fatty Acids (Doconexent) Doconexent 200 mg Vitamin E (Alpha-Tocopherol) Alpha-Tocopherol 20 [iU] Iron (Iron) Iron 29 mg

Inactive Ingredients Ingredient Name Strength Gelatin   Sorbitol   Glycerin   Soybean Oil   Water   Yellow Wax   Anhydrous Dibasic Calcium Phosphate   Lecithin, Soybean   Titanium Dioxide   Sodium Thiosulfate   Sunflower Oil   Tocopherol   Ascorbyl palmitate   Caramel   FD&C Blue NO. 1   Corn Oil

Product Characteristics Color blue (Dark Blue) Score no score Shape OVAL (size 12 Oval Capsule) Size 10mm Flavor Imprint Code EV0070 Contains

Packaging # NDC Package Description Multilevel Packaging 1 0642-0070-30 5 BLISTER PACK In 1 BOX contains a BLISTER PACK 1 6 CAPSULE In 1 BLISTER PACK This package is contained within the BOX (0642-0070-30) 2 0642-0070-01 1 BLISTER PACK In 1 BOX contains a BLISTER PACK 2 4 CAPSULE In 1 BLISTER PACK This package is contained within the BOX (0642-0070-01)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		06/13/2011

Labeler - Everett Laboratories, Inc. (071170534)

Establishment
Name	Address	ID/FEI	Operations
Intergel Pharmaceutical Inc		964464114	manufacture

Establishment
Name	Address	ID/FEI	Operations
Nutra-Med Packaging, Inc.		022004902	pack

Revised: 05/2011Everett Laboratories, Inc.

Iohexol SAD

Iohexol SAD may be available in the countries listed below.

Ingredient matches for Iohexol SAD

Iohexol

Iohexol is reported as an ingredient of Iohexol SAD in the following countries:

• Denmark

International Drug Name Search

Urecholine

Generic Name: Bethanechol Chloride
Class: Parasympathomimetic (Cholinergic) Agents
VA Class: AU300
CAS Number: 590-63-6

Introduction

Cholinergic agonist.^a

Uses for Urecholine

Urinary Retention

Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the bladder with retention.^{104 a}

Preferred agent to other parasympathomimetic drugs because of its relatively localized effect on the urinary tract and relative lack of adverse cardiovascular effects.^a

Heartburn

Has been shown to produce symptomatic improvement and decrease antacid use in some patients with chronic refractory heartburn† and gastroesophageal reflux disease (GERD), including vagotomized and antrectomized patients.^a However, use has decreased because of adverse CNS effects; acid suppression therapy with other agents (e.g., proton-pump inhibitors, histamine H₂-receptor antagonists) is principally used.¹⁰⁵

Urecholine Dosage and Administration

Administration

Administer orally on an empty stomach (e.g., 1 hour before or 2 hours after a meal) to minimize nausea and vomiting.^{104 a}

Has been administered by sub-Q injection, but an injectable dosage form no longer is commercially available in the US.^a

Dosage

Available as bethanechol chloride; dosage expressed in terms of the salt.^{104 a}

Individualize dosage according to the type and severity of the condition.^{104 a}

Adults

Urinary Retention

Oral

Determine the minimum effective dosage by administering 5 or 10 mg every hour until a satisfactory response occurs or a maximum of 50 mg has been given.^{104 a}

Usual dosage: 10–50 mg 3–4 times daily. ^{104 a}

Heartburn†

Oral

25 mg 4 times daily has been given.^a

Special Populations

No special population dosage recommendations at this time.^a

Cautions for Urecholine

Contraindications

• 
  

  Hyperthyroidism.¹⁰⁴

  
  


• 
  

  Peptic ulcer.¹⁰⁴

  
  


• 
  

  Latent or active bronchial asthma.¹⁰⁴

  
  


• 
  

  Coronary artery disease (CAD).¹⁰⁴

  
  


• 
  

  Epilepsy.¹⁰⁴

  
  


• 
  

  Parkinsonism.¹⁰⁴

  
  


• 
  

  Pronounced bradycardia or hypotension.¹⁰⁴

  
  


• 
  

  Vasomotor instability.¹⁰⁴

  
  


• 
  

  Condition in which the strength or integrity of the GI or bladder wall is in question or when increased muscular activity of GI tract or urinary bladder might prove harmful (e.g., recent urinary bladder surgery, GI resection and anastomosis) or when there is possible obstruction of GI tract or bladder neck, spastic GI disturbances, acute inflammatory GI tract lesions, peritonitis, or marked vagotonia.¹⁰⁴

  
  


• 
  

  Known hypersensitivity to the drug or any ingredient in the formulation.¹⁰⁴

  
  

Warnings/Precautions

General Precautions

Urinary Tract Infections

Risk of infection in patients with urinary retention and bacteriuria; if sphincter fails to relax, bethanechol-induced bladder contraction may force urine up ureter into kidney pelvis, causing reflux infection.¹⁰⁴

Cardiovascular Effects

May produce a slight, transient decrease in diastolic BP with mild reflex tachycardia.^{104 a} Patients with hypertension may react with a precipitous fall in BP.^{104 a}

Periods of atrial fibrillation reported in hyperthyroid patients following administration of cholinergic drugs.^a

Specific Populations

Pregnancy

Category C.¹⁰⁴

Lactation

Not known whether bethanechol is distributed into milk.^{104 a} Discontinue nursing or the drug.^{104 a}

Pediatric Use

Safety and efficacy not established.¹⁰⁴

Common Adverse Effects

Adverse effects rare after oral administration; more common after sub-Q injection (no longer commercially available in the US).¹⁰⁴ Adverse effects are most likely to occur when dosage is increased.^{104 a}

Abdominal cramps^{104 a} , colicky pain,^{104 a} flushing,^{104 a} sweating,^{104 a} salivation,^{104 a} malaise,^{104 a} headache,^{104 a} diarrhea,^{104 a} nausea,^{104 a} vomiting,^{104 a} bronchial constriction,^{104 a} urinary urgency,^{104 a} miosis.^{104 a}

Interactions for Urecholine

Specific Drugs and Laboratory Tests

Drug or Test	Interaction	Comments
Antiarrhythmic agents (e.g., procainamide, quinidine)	May antagonize effects of bethanechol a
Anticholinesterase agents (e.g., neostigmine)	Risk of additive effects and increased toxicity of bethanechol a	Avoid concomitant usea
Atropine	Antagonizes effects of bethanechol a	Interaction may be used to therapeutic advantage to counteract symptoms of bethanechol toxicitya
Cholinergic agents	Risk of additive effects and increased toxicity of bethanechol a	Avoid concomitant usea
Ganglion blocking compounds	Possible critical fall in BP and severe abdominal symptoms104 a	Use caution; monitor BP and abdominal symptoms104
Sympathomimetic agents (e.g., epinephrine)	Antagonizes effects of bethanechol at sites where adrenergic stimulation produces opposite effects from cholinergic stimulationa
Tests for serum amylase and lipase	Possible increase in serum amylase and lipase concentrationsa
Tests for serum aspartate aminotransferase, bilirubin, and sulfobromophthalein retention	Possible increase in concentrations by bethanechola

Urecholine Pharmacokinetics

Absorption

Bioavailability

Poorly absorbed from the GI tract.^a

Onset

Effects may be evident within 30 minutes after oral administration; usually, 60–90 minutes required to reach maximum effectiveness.^{104 a}

Administration by sub-Q injection produces a more intense action on bladder muscle than oral administration; however, an injectable dosage form no longer is commercially available in the US.^{104 a}

Duration

Usually, 1 hour following oral administration; however, large doses (300–400 mg) have been reported to produce effects for up to 6 hours.^{104 a}

Distribution

Extent

Does not cross the blood-brain barrier in usual doses.^{104 a} Distribution into other body fluids is largely unknown.^a

Elimination

Metabolic path and mode of excretion not known.^{104 a}

Stability

Storage

Oral

Tablets

Tight containers at 20–25°C.^{104 a}

ActionsActions

• 
  

  Synthetic ester structurally and pharmacologically related to acetylcholine.¹⁰⁴

  
  


• 
  

  Directly stimulates cholinergic receptors; stimulates ganglia to a lesser extent.^a

  
  


• 
  

  Effects are almost exclusively muscarinic; little, if any, nicotinic activity, and cardiovascular effects are negligible.^{104 a}

  
  


• 
  

  Increases tone and peristaltic activity in the stomach and intestines, increases esophageal peristalsis and the resting pressure of the lower esophageal sphincter, increases pancreatic and GI secretions, contracts detrusor muscle of urinary bladder, decreases bladder capacity, and increases frequency of ureteral peristaltic waves.^{104 a}

  
  

Advice to Patients

• 
  

  Inform patient to take 1 hour before or 2 hours after meals to avoid nausea or vomiting.¹⁰⁴

  
  


• 
  

  Risk of dizziness, lightheadedness, or fainting.¹⁰⁴ Use caution when rising from a lying or sitting position.¹⁰⁴

  
  


• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.^{104 a}

  
  


• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.^{104 a}

  
  


• 
  

  Importance of informing patients of other important precautionary information.^{104 a} (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Bethanechol Chloride

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Tablets	5 mg*	Urecholine (scored)	Duramed
		10 mg*	Urecholine (scored)	Duramed
		25 mg*	Urecholine (scored)	Duramed
		50 mg*	Urecholine (scored)	Duramed

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Bethanechol Chloride 10MG Tablets (TEVA PHARMACEUTICALS USA): 90/$89.99 or 270/$259.98

Bethanechol Chloride 25MG Tablets (WOCKHARDT USA): 90/$128.99 or 270/$361.95

Bethanechol Chloride 5MG Tablets (TEVA PHARMACEUTICALS USA): 90/$59.99 or 270/$159.96

Bethanechol Chloride 50MG Tablets (TEVA PHARMACEUTICALS USA): 90/$179.99 or 270/$529.96

Urecholine 10MG Tablets (ODYSSEY PHARMACEUTICALS INC.): 90/$119.99 or 270/$335.97

Urecholine 50MG Tablets (TEVA PHARMACEUTICALS USA): 90/$349.99 or 270/$1029.97

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

100. Guerra MF, Ives TJ. Bethanechol and hypothermia. Ann Intern Med. 1983; 99:279-80. [IDIS 173851] [PubMed 6136246]

103. Merck, West Point, PA: Personal communication.

104. Duramed Pharmaceuticals. Urecholine (bethanechol chloride) tablets prescribing informaiton. Pomona, NY; 2006 Nov.

105. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100:190-200. [PubMed 15654800]

a. AHFS drug information 2007. McEvoy GK, ed. Bethanecol. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1240-1241.

More Urecholine resources

• Urecholine Side Effects (in more detail)
• Urecholine Dosage
• Urecholine Use in Pregnancy & Breastfeeding
• Drug Images
• Urecholine Drug Interactions
• Urecholine Support Group
• 0 Reviews for Urecholine - Add your own review/rating

• Urecholine Prescribing Information (FDA)


• Urecholine MedFacts Consumer Leaflet (Wolters Kluwer)


• Urecholine Concise Consumer Information (Cerner Multum)


• Urecholine Advanced Consumer (Micromedex) - Includes Dosage Information


• Bethanechol Prescribing Information (FDA)

Compare Urecholine with other medications

• Abdominal Distension
• GERD
• Urinary Retention

Glucosamine Chondroitin MSM Complex

Generic Name: chondroitin, glucosamine, and methylsulfonylmethane (kon DROI tin, gloo KOSE a meen, and METH il sul FON il METH ane)

Brand Names: Glucosamine & Chondroitin with MSM, Glucosamine Chondroitin MSM Complex, Osteo Bi-Flex Advanced, Osteo Bi-Flex Plus MSM

What is Glucosamine Chondroitin MSM Complex (chondroitin, glucosamine, and methylsulfonylmethane)?

Chondroitin is a naturally occurring substance formed of sugar chains. Chondroitin is believed to help the body maintain fluid and flexibility in the joints.

Glucosamine is a naturally occurring substance that is believed to help develop and renew cartilage (the hard connective tissue mainly located on bones near joints in the body), and keep it lubricated for better joint movement and flexibility.

Methylsulfonylmethane is a naturally occurring form of sulfur that helps support muscles and tendons in the body.

The combination of chondroitin, glucosamine, and methylsulfonylmethane is used to aid in maintaining healthy joints. It is also used as a nutritional supplement in people with osteoarthritis or other inflammatory joint disorders.

Not all uses for chondroitin, glucosamine, and methylsulfonylmethane have been approved by the FDA. Chondroitin, glucosamine, and methylsulfonylmethane should not be used in place of medication prescribed for you by your doctor.

Chondroitin, glucosamine, and methylsulfonylmethane is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.

Chondroitin, glucosamine, and methylsulfonylmethane may also be used for purposes not listed in this product guide.

What is the most important information I should know about Glucosamine Chondroitin MSM Complex (chondroitin, glucosamine, and methylsulfonylmethane)?

Not all uses for this product have been approved by the FDA. Chondroitin, glucosamine, and methylsulfonylmethane should not be used in place of medication prescribed for you by your doctor.

Chondroitin, glucosamine, and methylsulfonylmethane is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.

Before using this product, talk to your doctor, pharmacist, herbalist, or other healthcare provider. You may not be able to use chondroitin, glucosamine, and methylsulfonylmethane if you have diabetes, a bleeding or blood clotting disorder such as hemophilia, if you have allergies to certain drugs, if you are overweight, or if you are on a low-salt diet.

Do not take chondroitin, glucosamine, and methylsulfonylmethane without the medical advice if you are using insulin, or a blood thinner such as warfarin (Coumadin, Jantoven). Avoid taking chitosan (usually marketed as a weight-loss product) while you are taking chondroitin, glucosamine, and methylsulfonylmethane. Chitosan can make it harder for your body to absorb chondroitin.

What should I discuss with my healthcare provider before taking Glucosamine Chondroitin MSM Complex (chondroitin, glucosamine, and methylsulfonylmethane)?

You should not use this product if you are allergic to it.

Ask a doctor, pharmacist, herbalist, or other healthcare provider if it is safe for you to use this product if you have:

• 
  

  diabetes;

  
  


• 
  

  a bleeding or blood clotting disorder such as hemophilia;

  
  


• 
  

  if you have allergies to certain drugs;

  
  


• 
  

  if you are overweight; or

  
  


• 
  

  if you are on a low-salt diet.

  
  

It is not known whether chondroitin, glucosamine, and methylsulfonylmethane will harm an unborn baby. Tell your healthcare provider if you are pregnant or plan to become pregnant while using this product. It is not known whether chondroitin, glucosamine, and methylsulfonylmethane passes into breast milk or if it could harm a nursing baby. Do not use this product without telling your healthcare provider if you are breast-feeding a baby.

How should I take Glucosamine Chondroitin MSM Complex (chondroitin, glucosamine, and methylsulfonylmethane)?

When considering the use of herbal supplements, seek the advice of your doctor. You may also consider consulting a practitioner who is trained in the use of herbal/health supplements.

If you choose to use chondroitin, glucosamine, and methylsulfonylmethane, use it as directed on the package or as directed by your doctor, pharmacist, or other healthcare provider. Do not use more of this product than is recommended on the label.

It may take up several weeks before your symptoms improve. Keep using the medication as directed and tell your doctor if your symptoms do not improve after a few weeks of treatment.

Glucosamine may increase the glucose (sugar) levels in your blood. If you have diabetes, you may need to check your blood sugar more often while taking this medication. You may also need to adjust your insulin dosage. Do not change your dose or medication schedule without advice from your doctor.

Chondroitin, glucosamine, and methylsulfonylmethane may be only part of a complete program of treatment that also includes diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely.

Store at room temperature away from moisture, heat, and light.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Glucosamine Chondroitin MSM Complex (chondroitin, glucosamine, and methylsulfonylmethane)?

Avoid taking chitosan (usually marketed as a weight-loss product) while you are taking chondroitin, glucosamine, and methylsulfonylmethane. Chitosan can make it harder for your body to absorb chondroitin.

Glucosamine Chondroitin MSM Complex (chondroitin, glucosamine, and methylsulfonylmethane) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:

• 
  

  mild nausea, upset stomach;

  
  


• 
  

  heartburn; or

  
  


• 
  

  diarrhea.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Glucosamine Chondroitin MSM Complex (chondroitin, glucosamine, and methylsulfonylmethane)?

Tell your doctor about all other medicines you use, especially:

• 
  

  insulin; or

  
  


• 
  

  a blood thinner such as warfarin (Coumadin, Jantoven).

  
  

This list is not complete and other drugs may interact with chondroitin, glucosamine, and methylsulfonylmethane. Tell your healthcare provider about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More Glucosamine Chondroitin MSM Complex resources

• Glucosamine Chondroitin MSM Complex Drug Interactions
• Glucosamine Chondroitin MSM Complex Support Group
• 1 Review for Glucosamine Chondroitin MSM Complex - Add your own review/rating

Compare Glucosamine Chondroitin MSM Complex with other medications

• Dietary Supplementation
• Osteoarthritis

Where can I get more information?

• Consult with a licensed healthcare professional before using any herbal/health supplement. Whether you are treated by a medical doctor or a practitioner trained in the use of natural medicines/supplements, make sure all your healthcare providers know about all of your medical conditions and treatments.